FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387168048> ?p ?o ?g. }

• W4387168048 endingPage "814" @default.
• W4387168048 startingPage "808" @default.
• W4387168048 abstract "Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) represent a breakthrough in the treatment of hypercholesterolemia. The aim of this study was to perform a multicentre prospective analysis on the effects of PCSK9i since their distribution in Italy.During the study period (July 2017 to February 2022) 246 patients (mean age 61 ± 11 years, male 73%) who were evolocumab (142/246) or alirocumab (104/246) new users were enrolled in the CERTI (Costo Efficacia Regione Toscana Inibitori PCSK9) study. Lipid value, adverse events (AEs), major cardiovascular events (MACEs) and intima-media thickness were analysed.PCSK9i therapy allowed a significant improvement in patients' lipid profile [total cholesterol -35%, P < 0.001; triglycerides -9%, P < 0.05; low-density lipoprotein (LDL) cholesterol -51%, P < 0.001; Lp(a) levels -4%, P < 0.05], maintained during the follow-up. No significant variations in intima-media thickness were observed. In the subgroup of patients with more than 1 year of PCSK9i therapy (165/246 patients) we highlighted: a 66% reduction in MACEs compared with the year before recruitment; a progressive increase in MACEs during the follow-up (MACEs event/rate at first year 0.08 vs. MACEs event/rate at year 5: 0.47); a patients cluster with late MACEs older, with higher prevalence of hypertension, smoking habit and peripheral vascular disease. During the follow-up, we recorded AEs in 31% of patients, which mainly resulted in reduction/discontinuation of lipid-lowering therapy for 50 patients or in discontinuation/shift of PCSK9i (respectively 8 and 6 cases).Our data agree with the large evidence on the effectiveness/tolerability of PCSK9i therapy; however, although PCSK9i represents a good cholesterol-lowering therapeutic option, our study shows a progressive increase in MACEs during the late follow-up that deserve further research." @default.
• W4387168048 created "2023-09-30" @default.
• W4387168048 creator A5000190629 @default.
• W4387168048 creator A5001694046 @default.
• W4387168048 creator A5034547255 @default.
• W4387168048 creator A5056510829 @default.
• W4387168048 creator A5060513215 @default.
• W4387168048 creator A5069720823 @default.
• W4387168048 creator A5086218234 @default.
• W4387168048 creator A5091481961 @default.
• W4387168048 date "2023-09-29" @default.
• W4387168048 modified "2023-10-03" @default.
• W4387168048 title "Major cardiovascular events increase in long-term proprotein convertase subtilisin/kexin type 9 inhibitors therapy: the Tuscany cost-effective study" @default.
• W4387168048 cites W2473272179 @default.
• W4387168048 cites W2617824116 @default.
• W4387168048 cites W2663206100 @default.
• W4387168048 cites W2895858833 @default.
• W4387168048 cites W2911964244 @default.
• W4387168048 cites W2920731821 @default.
• W4387168048 cites W2921557407 @default.
• W4387168048 cites W2989737745 @default.
• W4387168048 cites W2992678675 @default.
• W4387168048 cites W3039141343 @default.
• W4387168048 cites W3102991281 @default.
• W4387168048 cites W3107173064 @default.
• W4387168048 cites W3177940685 @default.
• W4387168048 cites W3183857127 @default.
• W4387168048 cites W3194546311 @default.
• W4387168048 cites W3211562667 @default.
• W4387168048 cites W3213401318 @default.
• W4387168048 cites W4200202934 @default.
• W4387168048 cites W4283654754 @default.
• W4387168048 cites W4294922091 @default.
• W4387168048 cites W4311093353 @default.
• W4387168048 cites W4380589342 @default.
• W4387168048 doi "https://doi.org/10.2459/jcm.0000000000001546" @default.
• W4387168048 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/37773882" @default.
• W4387168048 hasPublicationYear "2023" @default.
• W4387168048 type Work @default.
• W4387168048 citedByCount "0" @default.
• W4387168048 crossrefType "journal-article" @default.
• W4387168048 hasAuthorship W4387168048A5000190629 @default.
• W4387168048 hasAuthorship W4387168048A5001694046 @default.
• W4387168048 hasAuthorship W4387168048A5034547255 @default.
• W4387168048 hasAuthorship W4387168048A5056510829 @default.
• W4387168048 hasAuthorship W4387168048A5060513215 @default.
• W4387168048 hasAuthorship W4387168048A5069720823 @default.
• W4387168048 hasAuthorship W4387168048A5086218234 @default.
• W4387168048 hasAuthorship W4387168048A5091481961 @default.
• W4387168048 hasConcept C126322002 @default.
• W4387168048 hasConcept C164705383 @default.
• W4387168048 hasConcept C197934379 @default.
• W4387168048 hasConcept C2778114629 @default.
• W4387168048 hasConcept C2778163477 @default.
• W4387168048 hasConcept C2778715236 @default.
• W4387168048 hasConcept C2778824825 @default.
• W4387168048 hasConcept C2778849439 @default.
• W4387168048 hasConcept C2780072125 @default.
• W4387168048 hasConcept C2780745583 @default.
• W4387168048 hasConcept C2780948078 @default.
• W4387168048 hasConcept C43554185 @default.
• W4387168048 hasConcept C71924100 @default.
• W4387168048 hasConcept C90924648 @default.
• W4387168048 hasConceptScore W4387168048C126322002 @default.
• W4387168048 hasConceptScore W4387168048C164705383 @default.
• W4387168048 hasConceptScore W4387168048C197934379 @default.
• W4387168048 hasConceptScore W4387168048C2778114629 @default.
• W4387168048 hasConceptScore W4387168048C2778163477 @default.
• W4387168048 hasConceptScore W4387168048C2778715236 @default.
• W4387168048 hasConceptScore W4387168048C2778824825 @default.
• W4387168048 hasConceptScore W4387168048C2778849439 @default.
• W4387168048 hasConceptScore W4387168048C2780072125 @default.
• W4387168048 hasConceptScore W4387168048C2780745583 @default.
• W4387168048 hasConceptScore W4387168048C2780948078 @default.
• W4387168048 hasConceptScore W4387168048C43554185 @default.
• W4387168048 hasConceptScore W4387168048C71924100 @default.
• W4387168048 hasConceptScore W4387168048C90924648 @default.
• W4387168048 hasIssue "11" @default.
• W4387168048 hasLocation W43871680481 @default.
• W4387168048 hasLocation W43871680482 @default.
• W4387168048 hasOpenAccess W4387168048 @default.
• W4387168048 hasPrimaryLocation W43871680481 @default.
• W4387168048 hasRelatedWork W2475508510 @default.
• W4387168048 hasRelatedWork W2563888771 @default.
• W4387168048 hasRelatedWork W2746224452 @default.
• W4387168048 hasRelatedWork W2791439083 @default.
• W4387168048 hasRelatedWork W2807701282 @default.
• W4387168048 hasRelatedWork W3030370081 @default.
• W4387168048 hasRelatedWork W4238580056 @default.
• W4387168048 hasRelatedWork W4293579057 @default.
• W4387168048 hasRelatedWork W4311957178 @default.
• W4387168048 hasRelatedWork W1740842118 @default.
• W4387168048 hasVolume "24" @default.
• W4387168048 isParatext "false" @default.
• W4387168048 isRetracted "false" @default.
• W4387168048 workType "article" @default.